Xeris Biopharma Holdings, Inc. (XERS) Revenue Growth
Xeris Biopharma Holdings, Inc. (XERS) year-over-year revenue growth rate history. Analyze revenue growth in Excel with MarketXLS.
Revenue Growth Data
| Period | YoY Revenue Growth |
|---|---|
| 2022-12-31 | 122.32% |
| 2023-03-31 | -69.89% |
| 2023-06-30 | N/A |
| 2023-12-31 | N/A |
| 2024-12-31 | 23.89% |
| 2025-12-31 | 43.72% |
How XERS compares with sector peers
| Symbol | Company | Revenue growth (latest fiscal year) |
|---|---|---|
| NTRA | Natera Inc. | 35.90% |
| KRYS | Krystal Biotech Inc. | 33.94% |
| PODD | Insulet Corporation | 30.73% |
| KURA | Kura Oncology Inc. | 25.24% |
| NBIX | Neurocrine Biosciences Inc. | 21.45% |
These are five companies in the same sector as XERS with a comparable annual revenue growth. Each figure above is that company's most recent completed fiscal year, read from the same annual statements as the table on its own page, so the period end dates can differ between rows.
Get Xeris Biopharma Holdings, Inc. Data in Excel
Stream real-time stock prices and financials directly into your spreadsheets with MarketXLS.
Try: =hf_Revenue_Growth("XERS", 2024)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Volume |
| 2 | XERS | $8.53 | -0.70% | 1.03M |
| 3 | ||||
| 4 | ||||
| 5 |